CVD comprise the major cause of death in Western countries. Recent projections suggest that CVD will be the leading cause of death in both developed and developing regions of the world by the year 2020(Reference Murray and Lopez1). Epidemiological studies have associated the consumption of isoflavonoids with a lower incidence of CVD(Reference Adlercreutz, Markkanen and Watanabe2). In normal postmenopausal women, consuming whole soya foods with 60 mg isoflavones per d may help alleviate several key clinical risk factors for CVD(Reference Scheiber, Liu, Subbiah, Rebar and Setchell3).
HDL is synthesised in hepatic and intestinal cells and secreted as small particles containing phospholipids, free cholesterol, apoA-1 and apoE. Cholesterol synthesised or deposited in peripheral tissues is returned to the liver in a process referred to as ‘reverse cholesterol transport’. ApoA-1 activates lecithin–cholesterol acyltransferase and facilitates the removal of cholesterol from the tissues (as reviewed by Fielding & Fielding(Reference Fielding and Fielding4)). ApoA-1 is a major constituent of HDL at the structural as well as the functional levels. The promoter region of the human ApoA-1 gene has been characterised to be tissue-specific. In the liver, the transcription begins at 235 base pairs upstream to the translation start site(Reference Higuchi, Law, Hoeg, Schumacher, Meglin and Brewer5). Several cis enhancer or suppressor DNA-binding elements responding to changes in hormonal or metabolic status have been identified. An insulin response core element (IRCE) situated at − 411 to − 404 is responsible for insulin-(Reference Lam, Matsubara, Mihara, Zheng, Mooradian and Wong6) and epidermal growth factor-(Reference Zheng, Matsubara, Diao, Hollenberg and Wong7) induced gene expression. In the span from − 214 to − 119, three crucial elements: site A ( − 214 to − 192), site B ( − 169 to − 146) and site C ( − 134 to − 119) have been described for the binding of transcriptional factors and nuclear receptors(Reference Widom, Ladias, Kouidou and Karathanasis8).
ERα is a member of nuclear hormone receptors which bind a wide range of hydrophobic molecules, such as steroid hormone and phyto-oestrogens. ERα is found in various tissues, including liver, bone, heart and central nervous system(Reference Gustafsson9). Oestrogen binds to the C-terminal domain of ERα in the cytoplasm and releases the heat shock proteins. The activated ERα is translocated into the nucleus and seeks out genes with a specific response element for binding. The gene transcription machinery is then activated and the encoded mRNA is expressed.
Isoflavones are major phytooestrogens that have been the focus of many studies regarding their health benefits. Isoflavones share some common structure with the hormone oestrogen. Despite the similarity, the relative binding affinity of isoflavones for ERα is only 0·05–1 % of the binding affinity of 17β-oestradiol(Reference Shutt and Cox10). In contrast, their binding affinity for ERβ is approximately seven-fold greater than that of oestrogen. It is suggested that isoflavones may act as selective ER modulators(Reference Kuiper, Lemmen, Carlsson, Corton, Safe, van der Saag, van der Burg and Gustafsson11). In addition, the plasma isoflavone concentration can be several thousand times greater than that of oestradiol(Reference Adlercreutz12). They may compete for ER and display anti-oestrogenic effect, especially when endogenous oestrogen level is low.
Previous studies have shown that human hepatoma HepG2 cells can be a viable model for apo research(Reference Javitt13–Reference Zannis, Breslow, SanGiacomo, Aden and Knowles15) except that these cells do not express ERα(Reference Harnish, Evans, Scicchitano, Bhat and Karathanasis16). By using this cell model, this study was designed to investigate the regulatory mechanism of soya isoflavone on ApoA-1.
Materials and methods
Chemicals
Soya isoflavones were purchased from Sigma Chemicals (St Louis, MO, USA). PD98059, bisindolylmaleimide I, and 14–22 amide were obtained from EMD Biosciences Inc. (La Jolla, CA, USA). All other chemicals, if not stated, were acquired from Sigma Chemicals.
Cell culture
HepG2 cells (American Tissue Culture Collection, Rockville, MD, USA) were routinely cultured in RPMI–1640 media (Sigma Chemicals), supplemented with 10 % fetal bovine serum (Invitrogen Life Technology, Rockville, MD, USA) and antibiotics (50 U/ml penicillin, 50 μg/ml streptomycin), and incubated at 37°C and 5 % CO2. Three days before the experiment, the cultures were switched to RPMI–1640 phenol-red-free media (Sigma Chemicals) and 5 % charcoal–dextran-treated fetal bovine serum (Hyclone, Utah, USA). Sub-confluent cell cultures were treated with isoflavone with dimethylsulphoxide as the carrier solvent. The final concentration of the solvent was 0·1 % (v/v), and the control cultures received dimethylsulphoxide only.
Luciferase reporter gene assay
Construction of ApoA-1 activated luciferase reporter plasmids
Fragments from human ApoA-1 5′-flanking region were amplified from genomic DNA isolated from HepG2 cells. Primers were designed with the incorporation of Mlu I and Bgl II restriction sites. The forward primers for the respective constructs are listed in Fig. 1. They all shared the common reverse primer, 5′-ACA AGA TCT TTA GGG GAC ACC TAC CCG TCA-3′. The amplified product was then digested and subcloned into a firefly luciferase reporter vector pTA–Luc (BD Biosciences Clontech, Palo Alto, CA, USA), and the sequence accuracy was verified.
Dual luciferase assays
HepG2 cells were seeded at 105 cells/well in 24-well plates. After 24 h, the cells were transiently transfected with the reporter and ER expression plasmid at 0·4 μg each and 0·1 μg renilla luciferase control vector pRL (Promega, Madison, WI, USA) in LipofectAmine (Invitrogen Life Technologies). ERα and ERβ expression plasmids were generous gifts from Dr Donald Macdonald of Duke University, Northern Carolina. After 16 h, the medium was removed and the cells were treated with isoflavone for 24 h. The amounts of these two luciferases were determined using Dual-Luciferase Assay Kit (Promega). The luciferase bioluminescence was quantified by using a FLUOstar Galaxy plate reader. The transactivation activities of the ApoA-1 promoter represented by firefly luciferase light units were then normalised with that of renilla luciferase.
Quantitative real-time PCR assay
HepG2 cells were seeded in a six-well plate for 1 d and transfected with ERα expression plasmid or the empty vector pcDNA3.1. The medium was removed and cells were cultured with soya isoflavone. After 24 h of treatment, total RNA was extracted from the cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA). The concentration and purity of RNA were determined by absorbance at 260/280 nm. First DNA strands were synthesised from 3 mg total RNA using oligo-dT primers and M-MLV RT (USB Corporation, Cleveland, Ohio, USA). Target fragments were quantified by real-time PCR, and a DNA Engine Opticon™2 (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was employed for this assay. FAM™ dye-labelled TaqMan® MGB probes and primers for apoA-1 and glyceraldehyde-3-phosphate dehydrogenase (Assay-on-Demand™) and real-time PCR Taqman Universal PCR Master Mix were all obtained from Applied Biosystems (Foster City, CA, USA). PCR reactions were set up as described in the protocol, which was validated by the company. Signals obtained for glyceraldehyde-3-phosphate dehydrogenase was used as a reference housekeeping gene to normalise the amount of total RNA amplified in each reaction. Relative gene expression data were analysed using the 2-ΔΔCT method(Reference Livak and Schmittgen17).
Electrophoretic mobility shift assay
Nuclear protein extract was isolated by using NucBuster™ protein extraction kit (Novagen®; EMD Biosciences, Inc., La Jolla, CA, USA.). In brief, cells were washed, trypsinised, and packed at 500 g at 4°C. Reagent 1 was added to the packed cells. Nuclear extract was isolated from the cell suspension by vortexing and centrifugation. The nuclear protein was stored at − 80°C until assayed.
Because the deletion of IRCE consistently reduced the transactivation in 0·5 μm- and 10 μm-genistein as shown later in Fig. 4 (B), we pursued the binding activity with electrophoretic mobility shift assay. The annealed oligonucleotide of 2 × IRCE was labelled with T4 polynucleotide kinase (Novagen), and (γ32P)-ATP (Perkin Elmer Life and Analytical Sciences, Waltham, MA, USA). A spin column was used to purify the labelled probe. The nuclear protein was incubated with the labelled probe, sonicated salmon sperm DNA, poly(dI-dC), and binding buffer (400 mm- KCl, 80 mm-HEPES, 2 mm-dithiothreitol, 0·8 mm-EDTA, 80 % glycerol, pH 8) provided in electrophoretic mobility shift assay accessory kit (Novagen) for 30 min at room temperature. The reaction mix was then separated by a 6 % non-denaturing gel in 0·5 × Tris-borate EDTA at 100 V. The gel was dried and autoradiographed following the procedures in using a molecular imager FX (BioRad).
Statistical methods
A Prism® 3.0 software package (GraphPad Software, Inc., CA, USA) was utilised for statistical analysis. Results of this study were compared by ANOVA and Bonferroni's method for multiple comparisons. Significance level was set at P < 0·05.
Results
Effect of soya isoflavone on apoA-1 mRNA expression
Cultures transfected with ERα had a dose-dependent increase in apoA-1 mRNA abundance upon soya isoflavone treatment, whereas the apoA-1 expression in cells transfected with empty vector was not affected by the same treatment (Fig. 2). Isoflavone ranged from 0·1 μm to 1 μm could induce 2·5 to 20-fold increase in mRNA abundance, whereas oestradiol (E2) at 1 nm elicited about 7-fold increase. The inductions at 0·1, 0·5 and 1 μm-daidzein treatment appeared to be stronger, no difference and weaker, respectively, than their genistein counterparts at the same concentrations. No induction was observed in empty vector transfected cultures, and cultures transfected with ERα had a 3-fold higher apoA-1 mRNA expression than those transfected with control vector.
Response of ApoA-1 promoter to soya isoflavone in HepG2 cells expressing ERα
Following the real-time PCR experiment, we carried out reporter gene assays to verify the expression regulation. Significant elevations in the ApoA-1 promoter driven luciferase activity were demonstrated in ER-transfected cells treated with soya isoflavone at 0·5 μm or above (Fig. 3), and the increased activities ranging from 400 to 600 % were observed. Oestradiol at 1 nm also induced 6-fold increase in the normalised luciferase activities compared to the control.
Effect of protein kinase inhibitors and antioestrogen on ApoA-1 promoter driven luciferase activities in cultures expressing ERα
Previous studies(Reference Beers, Haas, Wong and Mooradian18, Reference Lamon-Fava and Micherone19) have indicated the involvement of protein kinase (PK) A, PKC or the mitogen-activated protein kinase (MAPK) in ApoA-1 regulation. Bisindolylmaleimide I, 14-22 amide, and PD98059 and are specific inhibitors for PKC, PKA, and MAPK, respectively. HepG2 cells were transfected with ERα for 1 d, and were then pre-treated with 1 μm-ICI 182, 780, 10 μm-PD 98 059, 10 μm-myristoylated PKI 14-22 amide, or 1 μm-bisindoylmaleimde I. Isoflavone or oestradiol was administered afterwards for 24 h. Compared to the control the administration of these inhibitors did not substantially decrease the ApoA-1 promoter-driven gene transactivation (Fig. 4). On the contrary, the MAPK and PKC inhibitors significantly increased the promoter activity. When the pure antioestrogen ICI 182730 was administered, the luciferase activity was reduced (P < 0·05) as demonstrated in Fig. 4. These data illustrated that ERα was involved in soya isoflavone-induced ApoA-1 transcriptional activation.
ApoA-1 promoter analysis in ER-positive HepG2 cells under soya isoflavone treatment
HepG2 cells were transfected with various ApoA-1 reporter constructs and ERα expression plasmid. Luciferase activity was subsequently measured to reveal the transcriptional control of apoA-1 expression. All ApoA-1 constructs displayed increasing trends when treated with increased concentrations of genistein (Fig. 5 (A)). In terms of the induced percentage, significant differences were observed between the IRCE and IRCE deletion onstructs, and the element-C and Cdel constructs at 0·5 μm- and/or 10 μm-genistein treatment. Under 10 μm-genistein treatment, only the signal given off by the IRCE stayed higher than the deletion construct. This indicated that IRCE was consistently activated by the soya isoflavone (Fig. 5 (B)).
DNA binding at IRCE under soya isoflavone treatment
The binding of nuclear protein isolated from ER-positive HepG2 cells to IRCE appeared to be inversely proportional to the concentration of genistein and daidzein (Fig. 6). At 10 μm- genistein or daidzein, the binding to this region was weakened as reflected by the optical density of the retarding band. Oestradiol at 1 nm also displayed a weaker band than the dimethylsulphoxide control (0·1 %). This result suggested that the isoflavones released the transcription suppression rather than encouraging the DNA binding at IRCE.
Discussion
In the present study, we found that soya isoflavone up regulated apoA-1 mRNA expression in HepG2 cells expressing ERα. ApoA-1 promoter-driven reporter gene assays supported evidence that the up regulation was introduced by increased transcriptional activities. The induction pathway appeared to be independent of MAPK, PKA, and PKC. Luciferase assays using the truncation reporter plasmids revealed the ICRE lying between − 412 and − 404 in the 5′flanking region of the ApoA-1 promoter could be important in the upregulation of transcription by genistein. Besides, genistein appeared to be a stronger inducer of apoA-1 expression than daidzein.
Genistein and 17β-oestradiol have been shown to increase the promoter activities of ApoA-1 in HepG2 cells(Reference Lamon-Fava, Ordovas and Schaefer20, Reference Lamon-Fava21). Similarly, the present study demonstrated that soya isoflavone activated both the apoA-1 mRNA expression and ApoA-1 promoter activity. The phytooestrogen soya isoflavone appeared to activate ERα for the induction of mRNA expression of apoA-1, and the condition has not been established in the studies mentioned earlier. It has been shown that a MAPK activation pathway is increased in the up regulation of ApoA-1-gene expression by genistein and 17β-oestradiol in wild type HepG2 cells(Reference Beers, Haas, Wong and Mooradian18). Conversely, it has been shown that overexpressing MAPK1/2 suppresses rather than promotes the transcriptional activities(Reference Beers, Haas, Wong and Mooradian18). Our study indicated that inhibition of several signalling pathways including MAPK, PKC and PKA pathways did not abolish the augmented ApoA-1 transcription, which is consistent with the latter study. This suggested that the up regulation of ApoA-1 transcriptional activity in the presence of ERα was not going through these signalling pathways. Some of the kinase inhibitors appeared to stimulate apoA-1 transactivation. The underlying mechanisms warrant further investigation.
Previous studies performed on the wild-type HepG2 cells have shown that oestrogen and genistein increase luciferase reporter activities of ApoA-1, and the increase in ApoA-1 gene promoter transactivities is mediated through the − 256 to − 41 region of the gene(Reference Lamon-Fava, Ordovas and Schaefer20, Reference Lamon-Fava21). This region contains binding sites for the transcription factors HNF-3β, HNF-4, and Egr-1. Sites at − 214 to − 192 and − 169 to − 146 have been shown containing response elements for HNF-4(Reference Harnish, Malik, Kilbourne, Costa and Karathanasis22) and HNF-3β(Reference Harnish, Malik and Karathanasis23), respectively. Binding sites for Egr-1 have also been located at − 221 to − 231 and − 189 to − 181(Reference Kilbourne, Widom, Harnish, Malik and Karathanasis24). However, the mRNA expressions in these studies have not been presented. In the present study, neither oestrogen nor soya isoflavone increased apoA-1 mRNA expression in HepG2 cells without ERα. It appears that the increased transactivities reported in these studies fail to bring forth a change at the mRNA level. On the other hand, cells transfected with ERα displayed a stronger increase in mRNA expression than the control even at the base level (0 μm). This increase of apoA-1 mRNA abundance was magnified when soya isoflavone or oestrogen was administered. Genistein or daidzein at 0·1 μm could significantly increase the mRNA amount in ER-positive HepG2 cells.
With respect to our truncation reporter experiments performed in HepG2 cells expressing ERα, deletion of IRCE significantly differentiates the transactivation activity under the treatment of 0·5 μm and 10 μm- genistein. This DNA binding site might be involved in the activation of ApoA-1 promoter activity. Many transcription factors interacting with insulin response element have been reported, such as Sp1(Reference Lam, Matsubara, Mihara, Zheng, Mooradian and Wong6), IRE-ABP(Reference Nasrin, Buggs, Kong, Carnazza, Goebl and Alexander-Bridges25), FOXO1a, FOXO3a, FOXO4a(Reference Onuma, Vander Kooi, Boustead, Oeser and O'Brien26), etc. Upon the binding to the insulin-sensitive DNA motif, some factors are activating to the transcription while the others are suppressive. In the present study, our electrophoretic mobility shift assay result suggested that the IRCE binding could be a blockage rather than inductive in the context of soya isoflavone-induced, ApoA-1-driven transactivity. Since the difference in transactivity with and without IRCE was about 20 % as shown in the 10 μm-genistein treatment shown in Fig. 4 (B), IRCE could be a part of the binding regions of several co-activators. The binding protein could also be unrelated to apoA-1 transactivation. Considering that the segment between − 41 and − 256 is reported to be sufficient and specific for maximal ApoA-1 transcription in HepG2 cells(Reference Sastry, Seedorf and Karthanasis27), further investigation is required to pinpoint the exact transcriptional mechanism.
Oestrogen replacement therapy has long been used for controlling postmenopausal symptoms, including lowering blood cholesterol. Lamon-Fava et al. (Reference Lamon-Fava, Ordovas and Schaefer20) have demonstrated that oestradiol increases promoter activities of ApoA-1 in HepG2 cells. An ER-independent pathway has also been described(Reference Zhang, Jiao, Bhavnani and Tam28) for equine oestrogen in the up regulation of ApoA-1 promoter activity. In contrast, oestrogen may repress apoA-1 expression. Harnish et al. (Reference Harnish, Evans, Scicchitano, Bhat and Karathanasis16) observed that 100 nm- oestradiol represses ApoA-1 promoter activity in HepG2 cells stably expressing ERα. These contradictory observations can be explained by differences in the oestrogen concentration, timing, or the model nature.
In summary, the present study demonstrated that soya isoflavone at physiologically relevant concentrations can up regulate ApoA-1 transcription in HepG2 cells transfected with ERα, but not in the wild-type cells.
Acknowledgements
This study was supported by the Chinese University of Hong Kong Direct Grant for Research code no. 2041184. There are no conflicts of interest for work performed in this paper.